ALKERMES | ALKS - Net Income


ALKERMES reported $82.76M in Net Income for its fiscal quarter ending in September of 2025.





Net Income Change Date
AbbVie USD 1.82B 1.63B Dec/2025
Acadia Pharmaceuticals USD 71.78M 45.11M Sep/2025
ALKERMES USD 82.76M 4.34M Sep/2025
Amgen USD 1.33B 1.88B Dec/2025
Biogen USD 466.5M 168.3M Sep/2025
BioMarin Pharmaceutical USD -30.74M 271.28M Sep/2025
Bristol-Myers Squibb USD 1.09B 1.11B Dec/2025
Coherus Biosciences USD -56.57M 5.87M Mar/2025
Eli Lilly USD 6.64B 1.05B Dec/2025
Gilead Sciences USD 2.18B 869M Dec/2025
Heron Therapeutics USD -4.85M 4.39M Sep/2024
Ionis Pharmaceuticals USD -128.61M 252.16M Sep/2025
J&J USD 5.12B 36M Dec/2025
Malin Corporation EUR -1.1M 2.2M Dec/2023
Merck USD 2.96B 2.82B Dec/2025
Minerva Neurosciences USD 1.44M 21.07M Dec/2024
Nektar Therapeutics USD -37.06M 15.31M Sep/2024
Neurocrine Biosciences USD 209.5M 102M Sep/2025
Otsuka Holdings JPY 65.49B 58.64B Dec/2025
Ovoca Bio EUR -5.65M 3.28M Jun/2022
Pfizer USD -1.65B 5.19B Dec/2025
Regeneron Pharmaceuticals USD 844.6M 615.4M Dec/2025
Vertex Pharmaceuticals USD 1.19B 108.2M Dec/2025